Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors (VASTUS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-06

Study Completion Date

2024-06-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a Phase 1b/2a basket trial to assess safety and efficacy of IDX-1197 in patients with HRR mutation.

There are two parts to this study: Phase 1b, IDX-1197 dose-selection study to determine RP2D and Phase 2a, non-randomized parallel dose expansion study to confirm RP2D.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

NCT03317743

Advanced Solid Tumors

COMPLETED PHASE1

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

NCT07020221

Pancreatic Ductal Adenocarcinoma Non Small Cell Lung Cancer Colorectal Cancer +2 more

RECRUITING PHASE1/PHASE2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

NCT06395519

Advanced or Metastatic Solid Tumors Breast Cancer Ovarian Cancer +10 more

RECRUITING PHASE1/PHASE2

K-BASKET, TAS-117, PI3K/AKT Gene Aberration

NCT03017521

Solid Tumor, Adult

COMPLETED PHASE2

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

NCT00474760

Sarcoma, Ewing's

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors Homologous Recombination Repair Gene Mutation Homologous Recombination Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IDX-1197

Patient will be receive IDX-1197HCl once daily for 28 continuous days

Group Type EXPERIMENTAL

IDX-1197

Intervention Type DRUG

Until progression or unacceptable toxicity develops

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IDX-1197

Until progression or unacceptable toxicity develops

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed cancers that have HRR mutation and are failed to standard therapy or for which standard or curative therapy does not exist or is not considered appropriate by the Investigator.
* Measurable disease according to RECIST, v1.1.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2
* Must have recovered from all side effects of their most recent systemic or local treatment (\<CTCAE grade 3)
* Life expectancy greater than 12weeks

Exclusion Criteria

* Prior treatment with PARP inhibitors
* Symptomatic CNS metastases
* History of or known carcinomatous meningitis
* Concurrent administration of any anti-cancer therapies other than those administered in this study
* Pregnant or lactating women
* Refractory nausea and vomiting, malabsorption, total gastrectomy, external biliary shunt or significant bowel resection that would preclude adequate absorption.
* Uncontrolled medical illness (such as infection requiring treatment with intravenous antibiotics)
* Severe or unstable angina, myocardial infarction or ischemia requiring coronary artery bypass graft or stent within the previous 6 months, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to enrollment or New York Heart Association (NYHA) Class II to IV heart disease.
* Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV)
* Known hypersensitivity to IDX-1197 or any of the excipients of the product

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No